Abstract:Weixian Liu, 1, 2 Xinxian Huang, 1– 3 Weizhao Luo, 1, 2 Xinguang Liu, 1, 2 Weichun Chen 1, 2 1 Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Institute of Aging Research, Guangdong Medical University, Dongguan, People's Republic of China; 2 Institute of Biochemistry & Molecular Biology, Guangdong Medical University, Zhanjiang, People's Republic of China; 3 School of Medical Technology, Guangdong Medical University, Dongguan, People's Republic of China Correspondence: Xinguang Liu; Weichun Chen, Tel +86-13922926543 ; +86-13694959795, Email ; Objective: Progerin, the underlying cause of Hutchinson-Gilford Progeria Syndrome (HGPS), has been extensively studied for its impact on normal cells and premature aging patients. However, there is a lack of research on its specific effects on tumor cells. Melanoma is one of the most common malignant tumors with high morbidity and mortality. This study aimed to elucidate the potential therapeutic role of progerin in melanoma. Materials and Methods: We constructed the melanoma A375 cell line and M14 cell line with stable expression of progerin. The expression of progerin, paxillin, and epithelial-mesenchymal transition (EMT) marker proteins in each cell group was measured using Western blot. The migration, proliferation, and cell cycle of cancer cells were assessed using the transwell assay, wound healing assay, colony formation assay, CCK 8 assay, and flow cytometry. RT-qPCR technology was used to examine the impact of progerin overexpression on microRNA expression. Finally, we transfected paxillin into the progerin overexpression cell group to verify whether progerin regulates the phenotype of tumor cells through paxillin. Results: Our study demonstrated that overexpression of progerin leads to decreased expression of paxillin and inhibits cancer cell migration, proliferation, EMT process and cell cycle progression. Additionally, rescue experiments revealed that the migration, proliferation ability, and EMT marker protein expression in progerin overexpressing cancer cells could be partially restored by transfecting a plasmid containing the paxillin gene. Mechanistic investigations further revealed that progerin achieves this inhibition of paxillin expression by upregulating miR-212. Conclusion: This study reveals that progerin may inhibit the migration and proliferation of melanoma cells through the miR-212/paxillin axis, which provides a new approach for the future treatment of this disease. Keywords: progerin, paxillin, migration, proliferation, melanoma Melanoma is a prevalent type of tumor that has been on the rise in recent years, 1 posing a significant threat to human life. Currently, treatment options for melanoma consist of targeted therapy, immunotherapy, and surgical resection. However, these approaches have certain limitations. It is worth noting that aging, much like cancer, is a separate yet interconnected phenomenon. Senescence is both a tumor suppressor response and a cancer promoter. 2,3 Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare progeria disease, which is an ideal model for studying aging, and the average life expectancy of patients is only 14.6 years. 4 HGPS is caused by a single base mutation (G608G) in the LMNA gene. This mutation leads to the permanent farnesylation of the lamin A precursor, resulting in the production of progerin. 5–7 In comparison to lamin A, progerin is deficient in 50 amino acid residues in its C-terminus, resulting in the absence of the ZMPSTE24 protease cleavage site. This absence enables progerin to retain a farnesyl group at its C-terminus. 8 The production of progerin triggers a cascade of events, including nuclear deformity, accumulation of DNA damage, and disruption of chromatin organization. These events lead to accelerated aging of cells, ultimately resulting in premature aging of patients. 9–11 As individuals age and accumulate DNA damage, the likelihood of developing tumors gradually increases. However, it is worth noting that individuals with HGPS do not develop childhood tumors. 12 The HGPS model provides a unique opportunity to investigate the connection between aging and tumors. Consequently, many scholars have become interested in the potential of using cellular senescence induction as a method to treat cancer. Research has demonstrated that the administration of multiple chemotherapy drugs that induce senescence can effectively trigger senescence in cancer cells. Additionally, activating the senescence response through p53 activation, inhibition of c-MYC in tumors, or treatment with cyclin-dep -Abstract Truncated-

Progerin Inhibits the Proliferation and Migration of Melanoma Cells by Regulating the Expression of Paxillin

Overexpression of Progerin Results in Impaired Proliferation and Invasion of Non-Small Cell Lung Cancer Cells

Progerin Induces Cell Cycle Arrest by Targeting CDK4 in HEK293T

Progerin modulates the IGF-1R/Akt signaling involved in aging

[Progerin and Its Role in Accelerated and Natural Aging]

Progerin Can Induce DNA Damage in the Absence of Global Changes in Replication or Cell Proliferation

Heterochromatin loss as a determinant of progerin‐induced DNA damage in Hutchinson–Gilford Progeria

Vascular senescence in progeria: role of endothelial dysfunction

Nuclear envelope budding inhibition slows down progerin-induced aging process

Molecular insights into the premature aging disease progeria

p53 isoforms regulate premature aging in human cells

Progerin Expression Induces Inflammation, Oxidative Stress and Senescence in Human Coronary Endothelial Cells

Unique progerin C-terminal peptide ameliorates Hutchinson–Gilford progeria syndrome phenotype by rescuing BUBR1

Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice

Progeria-based vascular model identifies networks associated with cardiovascular aging and disease

The Pathogenic Mechanisms and Therapeutic Strategies of Hutchinson-Gilford Progeria Syndrome

Mitophagy Defect Mediates the Aging-Associated Hallmarks in Hutchinson-Gilford Progeria Syndrome

Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture

The syntaxin-binding protein STXBP5 regulates progerin expression

Progerin accelerates atherosclerosis by inducing endoplasmic reticulum stress in vascular smooth muscle cells

All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype